Nipro Overview
- Founded
-
1954
- Status
-
Public
- Employees
-
37,235
- Stock Symbol
-
8086
- Investments
-
24
- Share Price
-
$8.01
- (As of Tuesday Closing)
Nipro General Information
Description
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
Contact Information
Primary Industry
Medical Supplies
Other Industries
Pharmaceuticals
Stock Exchange
TKS
Primary Office
- 3-9-3 Honjo-Nishi Kita-ku
- Osaka, 531-8510
- Japan
+81 00-0000-0000
Nipro Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.01 | $8.03 | $7.43 - $12.78 | $1.31B | 163M | 393K | $0.73 |
Nipro Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 5,658,229 | 5,658,229 | 6,772,230 | 6,174,147 |
| Revenue | 4,404,261 | 4,404,261 | 4,296,125 | 4,069,768 |
| EBITDA | 648,664 | 648,664 | 598,598 | 315,214 |
| Net Income | 119,767 | 119,767 | 133,997 | (112,947) |
| Total Assets | 7,622,585 | 7,622,585 | 7,745,014 | 7,697,247 |
| Total Debt | 4,628,115 | 4,628,115 | 4,942,936 | 5,008,834 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Nipro Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nipro Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in f
Medical Supplies
Osaka, Japan
37,235
As of 2022
00000000
000000
dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore ma
0000000 00000000
Tokyo, Japan
00000
As of 0000
00000000
0000 0
ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et do
0000000 00000000
Exton, PA
00000
As of 0000
00000000
Add Comparison
Nipro Competitors (13)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Terumo | Corporation | Tokyo, Japan | 00000 | 00000000 | ||
| 0000 0000000000000 | Corporation | Exton, PA | 00000 | 00000000 | ||
| 000000000000000 00 | Corporation | Lagos, Nigeria | 00 | |||
| 00000000 000000 00 | Corporation | Weihai, China | 00000 | 00000 | 000000 - 000 | 00000 |
| 000000 0000000 | Corporation | Kobe, Japan | 0000 | 00000000 |
Nipro Patents
Nipro Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210383531-A1 | Foreign matter inspection system and foreign matter inspection method | Pending | 31-Oct-2018 | 0000000000 | |
| DE-102018006961-A1 | Hollow glass body and use of a hollow glass body | Pending | 03-Sep-2018 | 000000000 | |
| DE-102018006968-A1 | Method for separating a hollow glass body from a glass tube and method and system for producing a container | Pending | 03-Sep-2018 | 000000000 | |
| EP-3847137-A1 | Hollow glass body and use of a hollow glass body | Pending | 03-Sep-2018 | 000000000 | |
| EP-3847138-A1 | Method for separating a hollow glass body from a glass tube as well as method and system for manufacturing a receptacle | Pending | 03-Sep-2018 | A61J1/065 |
Nipro Executive Team (5)
Nipro Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 00000000 | Nipro | Board Member | 000 0000 |
| 00000000 00000000 | Nipro | Board Member & General Manager | 000 0000 |
| 0000000 000000000 | Nipro | Board Member & General Manager | 000 0000 |
| 00000000 000000 | Nipro | Board Member & General Manager | 000 0000 |
| 000000000 0000 | Nipro | Board Member & President | 000 0000 |
Nipro Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Nipro Investments & Acquisitions (24)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 (000 | 03-Apr-2021 | 0000000000 | Other Containers and Packaging | 000000000 | |
| 000000 000000 | 28-Oct-2020 | 0000 00000 | 00.00 | Therapeutic Devices | 00000000 |
| 0000000 000 | 03-Mar-2020 | 0000000000 | Specialty Chemicals | 000000 00 | |
| 000000000 000 | 01-Jan-2018 | 0000000000 | Surgical Devices | ||
| TC Biopharm | 18-Jan-2017 | Early Stage VC | 00.000 | Drug Discovery |
Nipro Subsidiaries (8)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Dimesol USA | Specialty Chemicals | Lewisberry, PA | 2016 |
| 0000 0000000 & 000 | Biotechnology | Aoba-ku, Japan | 0000 |
| 000000000 | Diagnostic Equipment | Burlington, MA | 0000 |
| 00000 000000 | Mechelen, Belgium | 0000 | |
| 00000000 (0000000) | Other Containers and Packaging | Sesvete, Croatia | 0000 |
Nipro Exits (3)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 000000 | 15-Mar-2010 | 000000000000000000 | 00000 | Completed |
|
| 000000000 | 07-Oct-2008 | 00000 00000 00 | 00.000 | Completed |
|
| Bipha | 01-Feb-2001 | Secondary Transaction - Private | Completed |